RA Trial Finds 82% Remission After 10 Years

Rheumatoid arthritis research spans a broad treatment pipeline, with more than 75 companies developing over 80 therapies, according to a commercial pipeline report. In an ex vivo study of immune cells from patients with RA, baricitinib and etanercept reduced measures including cell proliferation and adhesion, while etanercept produced a stronger reduction in neutrophil NETosis markers; these laboratory findings do not establish clinical effectiveness. Long-term follow-up of participants in a Norwegian treat-to-target trial found that 82% of those assessed were in remission 10 years later, with limited radiographic joint damage, supporting the strategy’s potential for durable disease control.